Infantile Spasms Clinical Trial
Official title:
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
NCT number | NCT01413711 |
Other study ID # | 13453A |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 4 |
First received | June 17, 2011 |
Last updated | September 12, 2012 |
Start date | June 2012 |
Verified date | September 2012 |
Source | Lundbeck LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of the study is to evaluate vigabatrin pharmacokinetics (PK) in neonates receiving vigabatrin for infantile spasms (IS); and to determine the safety of vigabatrin.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Month to 6 Months |
Eligibility |
Inclusion Criteria: - The patient's parent or legally authorized representative is able to read and understand the Patient Information Sheet and Informed Consent Form. - The patient's legally authorized representative has signed the Informed Consent Form. - The patient has IS, diagnosed according to the International League Against Epilepsy (ILAE) criteria. - The patient is a full term (38 weeks gestation) male or female, aged >=1 month to <6 months at the time of enrollment. - The patient's length and body weight for gestational age is >=5th and <=95th percentile, according to Centers for Disease Control and Prevention (CDC) Growth Charts. Exclusion Criteria: - The patient is currently being treated or has been previously treated with vigabatrin. - The patient is a member of the site personnel's immediate family. - The patient takes or has taken disallowed recent or concomitant medication or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study. - The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to the investigational medicinal product (IMP) or the excipients (povodone/iodine) of the IMP. - The patient has any other disorder for which the treatment takes priority over treatment of IS or is likely to interfere with study treatment or impair treatment compliance. - The patient has been treated with any IMP within 30 days or 5 half lives (whichever is longer) prior to the Screening Visit. - The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. - The patient has been diagnosed or is judged by the investigator to have anemia. - The patient has been diagnosed or is judged by the investigator to have renal insufficiency. - The patient's parent or legally authorized representative is, in the investigator's opinion, unlikely or unwilling to comply with the protocol or the patient is unsuitable for any reason. |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lundbeck LLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-compartmental pharmacokinetic profile of vigabatrin after oral administrations in infants(>=1 and <6 months of age) | Serial blood for plasma generation will be collected on Days 1 and 5 and vigabatrin concenrations determined to the determine the pharmacokinetic profile of vigabatrin | 24 hrs post dose on Day 1 and 12 hrs post dose on Day 5 | Yes |
Secondary | To determine the safety of vigabatrin following oral dose administrations in infants (>=1 and <6 months of age) | Safety and tolerability parameters such as adverse events, clinical safety laboratory tests and vital signs will be summarised using descriptive statistics | Safety collected throughout the 5-day study | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02299115 -
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
|
Phase 3 | |
Completed |
NCT02885389 -
Molecular Genetics in Infantile Spasms
|
N/A | |
Completed |
NCT01006811 -
Use of the Modified Atkins Diet in Infantile Spasms
|
Phase 2/Phase 3 | |
Completed |
NCT01828437 -
Addition of Pyridoxine to Prednisolone in Infantile Spasms
|
Phase 3 | |
Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
Completed |
NCT00552045 -
Epilepsy Phenome/Genome Project
|
||
Completed |
NCT02220114 -
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
|
N/A | |
Completed |
NCT02954887 -
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
|
Phase 3 | |
Completed |
NCT02092883 -
Evaluation of Neuroinflammation in Children With Infantile Spasms
|
Phase 4 | |
Completed |
NCT01723787 -
Genetic Studies in Patients and Families With Infantile Spasms
|
||
Terminated |
NCT00442104 -
Open-label Extension to Protocol 1042-0500
|
Phase 2 | |
Completed |
NCT00441896 -
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
|
Phase 2 | |
Completed |
NCT01575639 -
Prednisolone in Infantile Spasms- High Dose Versus Usual Dose
|
Phase 3 | |
Withdrawn |
NCT01549288 -
Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06315829 -
Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
|
||
Completed |
NCT01073579 -
Sabril Patient Registry
|
N/A | |
Completed |
NCT02953548 -
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
|
Phase 3 | |
Completed |
NCT00001325 -
Metabolic Abnormalities in Children With Epilepsy
|
N/A | |
Completed |
NCT00968136 -
Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
|
N/A |